Deal Aims to Grow “Humanized” Organs in Pigs for Transplantation

J. Craig Venter, Synthetic Genomics,

A San Diego startup that specializes in re-engineering genes and a multi-billion-dollar biotech giant in Silver Springs, MD, say they are now working together on an audacious goal—developing “humanized” organs in pigs that can be transplanted into humans.

Under a multi-year R&D collaboration being announced today, San Diego-based Synthetic Genomics and Lung Biotechnology, a subsidiary of United Therapeutics (NASDAQ: [[ticker:UTHR]]), intend to eliminate the genomic incompatibilities that lead to rejection in lung transplants. The United Therapeutics subsidiary agreed to make a $50 million investment in Synthetic Genomics as part of the deal.

The ambitious effort is the latest example of the unfurling potential in genomic medicine—and also the latest quest put forward by J. Craig Venter, the pioneer in human genome sequencing who co-founded Synthetic Genomics in 2005 with the Nobel laureate Hamilton Smith. Just two months ago, Venter announced that he was starting a new company to sequence the entire genomes of thousands of people in a bid to identify and repair the genetic causes of age-related diseases like cancer and heart disease.

The problem with human lung transplantation, Venter said by telephone yesterday, is there are nowhere near enough human organs available to meet the need. “We need a ready source [of donor lungs], and the genetic tools are now available,” he said.

Even with the tools, though, the challenge is both enormous and complex. Venter says the concept of developing humanized lungs calls for modifying a substantial number of genes in pig cells. According to a joint statement from the two companies, United Therapeutics would then use its expertise in xenotransplantation “to implant these engineered cells, generating pig embryos which develop and are born with humanized lungs.”

This phrasing is a little vague, and I should have asked Venter how, exactly, this would be done. As I understand it, the process would modify the genes of a pig zygote—the cell formed after initial fertilization—so the lungs of a pig embryo (or many pig embryos) would develop “humanized” lungs designed specifically to minimize their genetic incompatibilities with human hosts.  These pig embryos would be implanted in sows and birthed. The piglets would continue to grow to maturity, or until their genetically modified lungs could be

Author: Bruce V. Bigelow

In Memoriam: Our dear friend Bruce V. Bigelow passed away on June 29, 2018. He was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Bruce Bigelow joined Xconomy from the business desk of the San Diego Union-Tribune. He was a member of the team of reporters who were awarded the 2006 Pulitzer Prize in National Reporting for uncovering bribes paid to San Diego Republican Rep. Randy “Duke” Cunningham in exchange for special legislation earmarks. He also shared a 2006 award for enterprise reporting from the Society of Business Editors and Writers for “In Harm’s Way,” an article about the extraordinary casualty rate among employees working in Iraq for San Diego’s Titan Corp. He has written extensively about the 2002 corporate accounting scandal at software goliath Peregrine Systems. He also was a Gerald Loeb Award finalist and National Headline Award winner for “The Toymaker,” a 14-part chronicle of a San Diego start-up company. He takes special satisfaction, though, that the series was included in the library for nonfiction narrative journalism at the Nieman Foundation for Journalism at Harvard University. Bigelow graduated from U.C. Berkeley in 1977 with a degree in English Literature and from the Columbia University Graduate School of Journalism in 1979. Before joining the Union-Tribune in 1990, he worked for the Associated Press in Los Angeles and The Kansas City Times.